Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adial Pharmaceuticals Inc (ADIL) has issued an update.
Adial Pharmaceuticals, Inc. has announced the termination of its consulting agreement with Dr. Bankole A. Johnson, which will result in his departure from the role of Chief Medical Officer effective May 17, 2024. The agreement, in place since March 2019 and amended twice in 2022, marks a significant change in the company’s leadership structure.
For detailed information about ADIL stock, go to TipRanks’ Stock Analysis page.